

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LIFE HEALTHCARE GROUP LIMITED

蓮和醫療健康集團有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 928)

CHANGE OF DIRECTORS AND CHANGE IN COMPOSITION OF THE AUDIT COMMITTEE AND THE NOMINATION COMMITTEE

The Board hereby announces that with effect from 31 August 2020:

- (1) Mr. Zheng Chunlei has been resigned as an independent non-executive Director;
- (2) Ms. Fu Xiaoji has been appointed as a non-executive Director; and
- (3) Ms. Zheng Xin has been appointed as an independent non-executive Director.

The board (the “**Board**”) of directors (“**Directors**”) of Life Healthcare Group Limited (the “**Company**”) announces the followings:

RESIGNATION OF DIRECTOR

Mr. Zheng Chunlei (“**Mr. Zheng**”) has resigned as an independent non-executive Director of the Company, a member of the audit committee of the Company (“**Audit Committee**”) and a member of the nomination committee of the Company (“**Nomination Committee**”) with effect from 31 August 2020 to allow him to devote more time to his other business endeavours. Mr. Zheng has confirmed that he has no disagreement with the Board and there are no other matters relating to his resignation which need to be brought to the attention of the shareholders of the Company (the “**Shareholders**”).

The Board would like to express its gratitude and appreciation to Mr. Zheng for his contribution to the Company during his term of office.

APPOINTMENT OF DIRECTORS

- (a) The board is pleased to announce that Ms. Fu Xiaoji (“**Ms. Fu**”) has been appointed as a non-executive Director with effect from 31 August 2020.

Ms. Fu, aged 38, with a bachelor’s degree, is currently in charge of operations of Shenzhen BlueZone Technologies Co., Ltd. *(深圳藍色海潮科技有限公司) Ms. Fu has more than 10 years of experience in the Internet and mobile Internet industry, and has worked in Alibaba Group, WOOMI of South Korea and other well-known companies, with rich experience in Internet advertising and Internet medical industry.

Ms. Fu has not held (i) any other position in the Company and other members of the Group; (ii) any directorship in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; and (iii) any other major appointments and professional qualifications.

As the date of this announcement, Ms. Fu has no relationships with any Directors, senior management, substantial or controlling shareholders of the Company (having the meaning ascribed to it in the Rules Governing the Listing of Securities or the Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and does not have any interests in the securities of the Company within the meaning of Part XV of the Securities and Future Ordinance (Chapter 571 of the Laws of Hong Kong) (“**SFO**”).

Under the letter of appointment entered into between Ms. Fu and the Company, Ms. Fu’s term of service is 2 years. Her directorship in the Company is subject to rotation and re-election at annual general meetings of the Company in accordance with the articles of association of the Company. The remuneration of Ms. Fu is HK\$20,000 per month which is determined by the Board and the remuneration committee of the Company (“**Remuneration Committee**”) with reference to her experience, duties and responsibilities within the Company.

Save as disclosed above, there are no other matters relating to the appointment of Ms. Fu that need to be brought to the attention of the Shareholders and there is no other information that should be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

- (b) The board is pleased to announce that Ms. Zheng Xin (“**Ms. Zheng**”) has been appointed as an independent non-executive Director, a member of the Audit Committee and a member of the Nomination Committee with effect from 31 August 2020.

Ms. Zheng, aged 37, obtained her Juris Doctor degree and Juris Master degree from City University of Hong Kong in July 2019 and August 2016, respectively. Since 2014, Ms. Zheng has worked in Shanghai Allbright Law Offices (Shenzhen) *(上海市錦天城(深圳)律師事務所) and is responsible for the interface with clients in

* *For identification purpose only*

Hong Kong, Australia and the United States, participating in domestic and foreign capital market projects, including initial public offerings, mergers and acquisitions and restructuring. Ms. Zheng is well-versed in the laws of the healthcare industry and the rules of operation of the Hong Kong securities market and is an accredited mediator in Hong Kong and a Hong Kong arbitrator of CIarb (East Asia Branch). Prior to commencing her legal career, Ms. Cheng worked at Shenzhen Holy Medical Technology Development Co., Ltd. *(深圳市聖愛醫學科技發展有限公司) and has over 8 years of experience in the medical and technology industry.

Ms. Zheng has not held (i) any other position in the Company and other members of the Group; (ii) any directorship in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; and (iii) any other major appointments and professional qualifications.

As the date of this announcement, Ms. Zheng has no relationships with any Directors, senior management, substantial or controlling shareholders of the Company (having the meaning ascribed to it in the Listing Rules) and does not have any interests in the securities of the Company within the meaning of Part XV of the SFO.

Under the letter of appointment entered into between Ms. Zheng and the Company, Ms. Zheng's term of service is 2 years. Her directorship in the Company is subject to rotation and re-election at annual general meetings of the Company in accordance with the articles of association of the Company. The remuneration of Ms. Zheng is HK\$20,000 per month which is determined by the Board and the Remuneration Committee with reference to her experience, duties and responsibilities within the Company.

Save as disclosed above, there are no other matters relating to the appointment of Ms. Zheng that need to be brought to the attention of the Shareholders and there is no other information that should be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to express a warm welcome to Ms. Fu and Ms. Zheng for joining the Board.

By order of the Board
Life Healthcare Group Limited
Xu Xueping
Executive Director

Hong Kong, 31 August 2020

* *For identification purpose only*

As at the date of this announcement, the Board comprises:

Executive Directors:

Mr. Xu Xueping (*Chairman*)

Mr. Man Wai Lun

Mr. Yang Zhiying

Independent non-executive Directors:

Mr. Liu Xinghua

Mr. Cheng Chun Man

Ms. Zheng Xin

Non-executive Directors:

Ms. Shan Hua

Ms. Fu Xiaoji